IL6 and head and neck squamous cell carcinoma: The enrichment of immune pathways (“IL6 JAK STAT3 signaling”, “TNFa signaling via NFKB”, “inflammatory response”) in the T-without group highlighted this concept, suggesting a future integration of these genes in the ongoing trials with immunotherapy as adjuvant treatments for HNSCC.